Phase 3 Readout~month
Phase 3 Topline: A Phase 3, Double-blind, Multicenter, Randomized, Placebo-Controlled Study to Evaluate the Efficacy,
- Company
- Biohaven Ltd. (BHVN)
- Indication
- Graves Disease
Other upcoming events for BHVN
Phase 3 ReadoutPhase 3 Topline: A Phase 2/3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficac
Phase 3 ReadoutPhase 3 Topline: A Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Taldefg
Phase 3 ReadoutPhase 3 Topline: A Multi-Center, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safe
Track this catalyst and more
Get real-time alerts, AI-powered analysis, and full catalyst coverage.